2.50
Hdl Handle:
http://hdl.handle.net/10541/80141
Title:
ZD1839 (IRESSA): a selective EGFR-TK inhibitor.
Authors:
Ranson, Malcolm R; Mansoor, Was; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. malcolm.ranson@amn.ac.uk
Citation:
ZD1839 (IRESSA): a selective EGFR-TK inhibitor. 2002, 2 (2):161-8 Expert Rev Anticancer Ther
Journal:
Expert Review of Anticancer Therapy
Issue Date:
Apr-2002
URI:
http://hdl.handle.net/10541/80141
DOI:
10.1586/14737140.2.2.161
PubMed ID:
12113238
Type:
Article
Language:
en
ISSN:
1473-7140
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm R-
dc.contributor.authorMansoor, Was-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-09-07T15:40:56Z-
dc.date.available2009-09-07T15:40:56Z-
dc.date.issued2002-04-
dc.identifier.citationZD1839 (IRESSA): a selective EGFR-TK inhibitor. 2002, 2 (2):161-8 Expert Rev Anticancer Theren
dc.identifier.issn1473-7140-
dc.identifier.pmid12113238-
dc.identifier.doi10.1586/14737140.2.2.161-
dc.identifier.urihttp://hdl.handle.net/10541/80141-
dc.description.abstractThe recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshHumans-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.titleZD1839 (IRESSA): a selective EGFR-TK inhibitor.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. malcolm.ranson@amn.ac.uken
dc.identifier.journalExpert Review of Anticancer Therapyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.